Icon
+91 94997 68112
Login Register

LYRICA (nda021446)- (25MG,50MG,75MG,100MG,150MG,200MG,225MG,300MG)

PREGABALIN UPJOHN
25MG,50MG,75MG,100MG,150MG,200MG,225MG,300MG
Yes No
2019-Jun-30 Expired
None None
None No
LYRICA is indicated for:  Neuropathic pain associated with diabetic peripheral neuropathy (DPN)  Postherpetic neuralgia (PHN)  Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older  Fibromyalgia  Neuropathic pain associated with spinal cord injury
30 6 20
Total Other Developers 7
Drugs with Suitability No
25MG ** ** - - 15
50MG ** ** Up - 16
75MG ** ** Up - 17
100MG ** ** Up - 16
150MG ** ** Up - 17
200MG ** ** Up - 15
225MG ** ** Up - 14
300MG ** ** Up - 16
NDA Sales Available Total Generic Sales Available
Yes 15
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ******** **, ***** ****, *****, ****** ********, ********, ******* ******, ***** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** *********** ********, **** -** **. **'* (***** **) : ***, *** , ***, ***, ***, ***, ***, ***- *** *** *** ******** (*******), ********* (******),, ********** (********), ********* ******, ***** (***) ***
****** *** *** *************** *** *********** **, **** ****, **********, *** ****** (**) *****, ****** ****** (***) ***
****** ** ****** **. *****'* ************ ******* *********** ***-*** - ******* **** - **, ****** ** ******,**,**&**, ****** ** * ** ** & ** ** **, **************** ******* ***********(*),, **********, ****** ******* ******, ***** (***) ***
****** ****** ****** ** ****** *************** ** *** ****, *** *********** ** ********** **, **********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ****** ****** ** ****** ******* ******** ******** *** *********** *** ** ******* ***/***, ***********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ****** ****** **** ******* *********** **** **. **, ** & **, ******* ****** ***** *********** *******, ******** ******, **********, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ***** ***** ******* *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ***** *** ********** ******* ******* *** *********** **** **.: *** ** *** ,***-* ,*** ** *** & ***/ *,*,*,*, *****-**, *** ************, ************ (*******), ********** (******),, ********** ********, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *** ****** ****, ***** ********** ****, *****, *******, ****, ********** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******* ******** ****** ******* *********** **** ** *-** & *-**, ***** ********** ******,, *****, *** ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ****** ****** *** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***
****** ********* ** ********* *****, *** *********** ** *******-**, ******-***, *********-**, ********, **************-** *****, *****, ***** (***) ***
****** ********* ***** ********* ************** ******* *********** **.*** ******* **** ****, *********, ******* ******** ******, ***** (***) ***

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.